Patents by Inventor Nikhil Hebbar

Nikhil Hebbar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING GRP78 AND CD123 OR GRP78 AND B7H3
    Publication number: 20250195658
    Abstract: The application provides bispecific chimeric antigen receptors (CARs) targeting glucose-regulated-protein 78 (GRP78) and Cluster of Differentiation 123 (CD123) or GRP78 and B7-homolog 3 (B7H3). The application further provides polynucleotides and recombinant vectors encoding the CARs, as well isolated host cells and methods for preparing isolated host cells that express the CARs. The application further provides pharmaceutical compositions comprising the CAR modified cells and methods for treating a tumor using the CAR modified cells.
    Type: Application
    Filed: January 11, 2023
    Publication date: June 19, 2025
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
    Inventors: Mireya VELASQUEZ, Stephen GOTTSCHALK, Jaquelyn ZOINE, Nikhil HEBBAR
  • GRP78 TARGETED ADOPTIVE CELL THERAPY
    Publication number: 20230312671
    Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising an extracellular target-binding domain comprising at least one glucose-regulated-protein 78 (GRP78)-binding moiety. The present invention further provides polynucleotides and recombinant vectors encoding such CARs. The present invention further provides isolated host cells and methods for preparing isolated host cells expressing the CARs. The present invention further provides pharmaceutical compositions comprising the host cells and methods for treating a tumor using the pharmaceutical compositions.
    Type: Application
    Filed: April 23, 2021
    Publication date: October 5, 2023
    Applicant: St. Jude Children's Research Hospital, Inc.
    Inventors: Mireya Paulina VELASQUEZ, Stephen GOTTSCHALK, Nikhil HEBBAR, Rebecca EPPERLY, Abishek VAIDYA
  • USE OF PROTEASE SERINE 21 (PRSS21) ANTIGEN TESTING IN THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA
    Publication number: 20230016709
    Abstract: Methods for detection, diagnosis, prognosis, theragnosis, and targeted therapy of a PRSS21-overexpressing condition (e.g., cancer), in particular, PRSS21-overexpressing acute myeloid leukemia of the AMKL subtype.
    Type: Application
    Filed: November 24, 2020
    Publication date: January 19, 2023
    Applicant: St. Jude Children's Research Hospital
    Inventors: Stephen Gottschalk, Patrick Schreiner, Yiping Fan, Nikhil Hebbar, Myreya Paulina Velasquez